Funding Opportunity RFA-HL-20-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Funding Opportunity RFA-HL-20-024 from the NIH Guide for Grants and Contracts. This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

Funding Opportunity RFA-HL-20-023 from the NIH Guide for Grants and Contracts. This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Funding Opportunity RFA-HL-20-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This FOA is part of a suite of NHLBI Catalyze program to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.

Funding Opportunity PAR-19-370 from the NIH Guide for Grants and Contracts. The NIDCR Small Grant Program for New Investigators (R03) supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator initiated Research Project Grant (R01) or equivalent application.

Notice NOT-DK-19-022 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-367 from the NIH Guide for Grants and Contracts. The Maximizing Investigators' Research Award (MIRA) provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this program will: Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively; Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies; More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs; Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research; Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. This FOA allows both new applications from eligible NIGMS-funded investigators and renewal applications from current established and early-stage MIRA grantees.

Funding Opportunity PAR-19-366 from the NIH Guide for Grants and Contracts. The purpose of the Institutional Research and Academic Career Development Award (IRACDA) Program is to develop a diverse pool of well-trained scientists available to address the nation's biomedical research agenda. The program requires effective partnerships between a research-intensive institution and a teaching-intensive partner institution that has a historical mission or a demonstrated commitment to educating students from groups underrepresented in the biomedical research workforce. The IRACDA program provides support for a mentored postdoctoral research training experience at the research-intensive institution and funding for the IRACDA scholars to develop critical teaching and mentoring skills at a partner institution. The primary goals of the IRACDA program are to develop a diverse pool of well-trained biomedical scientists who have the necessary knowledge and skills to pursue independent academic careers and to enhance science educational offerings at partner institutions. This Funding Opportunity Announcement (FOA) does not allow appointed scholars to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

Notice NOT-HS-19-020 from the NIH Guide for Grants and Contracts

Notice NOT-MH-19-039 from the NIH Guide for Grants and Contracts

Notice NOT-TR-19-027 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-026 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-371 from the NIH Guide for Grants and Contracts. The purpose of the NIAID Career Transition Award (CTA) program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

Notice NOT-HL-19-709 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-19-015 from the NIH Guide for Grants and Contracts. The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. This FOA is to invite applications for Clinical Research Centers to build on foundational work to establish a longitudinal cohort study with the intent of identifying plausible targets for future intervention studies. The consortium will also conduct a range of additional studies to facilitate the success of future intervention and implementation studies.

Funding Opportunity RFA-DK-19-016 from the NIH Guide for Grants and Contracts. The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Scientific and Data Center to build on foundational work to establish a longitudinal cohort study with the intent of identifying plausible targets for future intervention studies. The consortium will also conduct a range of additional studies to facilitate the success of future intervention and implementation studies.

Funding Opportunity RFA-CA-19-051 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to currently funded NCI Specialized Center--Cooperative Agreements that will inform on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.

Funding Opportunity RFA-HD-20-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to address the needs of the maternal and pediatric HIV scientific community for research data translation and sharing. This initiative will support secondary data analyses using archived HIV/AIDS data and specimens to generate new research questions and findings relevant to the scientific mission and priorities of the NICHD, Maternal and Pediatric Infectious Disease Branch(MPIDB) and Office of AIDS Research (OAR). The goal of this initiative is to continue the encouragement of the scientific community to utilize HIV/AIDS archived data sets and specimen collections to answer important questions about the epidemiology, pathogenesis, treatment, clinical manifestations and complications of HIV/AIDS in maternal, pediatric and adolescent populations.

Notice NOT-HL-19-719 from the NIH Guide for Grants and Contracts

Notice NOT-AT-19-034 from the NIH Guide for Grants and Contracts